AD Scientific Index
 Open Nav
Login Login Pricing & Plans Pricing & Plans
Suresh Kumar Agarwal

Suresh Kumar Agarwal

BioMarin Pharmaceutical, Inc. - / United States
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4979830
person_outline Suresh Kumar Agarwal's MOST POPULAR ARTICLES
1-) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label … The lancet oncology 19 (2), 216-228, 2018
2-) Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study Journal of Clinical Oncology 37 (15), 1277-1284, 2019
3-) Efficacy of venetoclax as targeted therapy for relapsed/refractory t (11; 14) multiple myeloma Blood, The Journal of the American Society of Hematology 130 (22), 2401-2409, 2017
4-) Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study The lancet oncology 18 (2), 230-240, 2017
5-) Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments Clinical Therapeutics 39 (2), 359-367, 2017